Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

664
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
664
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell analyses identify the ginseng embryonic protoderm as a native compartment for high-efficiency ginsenoside production.

Nature communications·2026
Same author

Diplopia as the herald of fulminant myocarditis in undifferentiated connective tissue disease: a case report.

Frontiers in cardiovascular medicine·2026
Same author

Ultrasound localisation microscopy tracks testicular microvascular adaptations to endocrine function in male infertility.

EBioMedicine·2026
Same author

Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment.

Cell metabolism·2026
Same author

A Non-Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non-Small Cell Lung Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Five-year systemic complications in diabetic retinopathy with integrated optical coherence tomography angiography and glycated hemoglobin.

Frontiers in medicine·2026
Same journal

Dual-Targeted Radionuclide Therapy with <sup>161</sup>Tb Instigates Anticancer Immunity in "Cold" Murine Prostate Tumor.

Molecular pharmaceutics·2026
Same journal

Development of [<sup>111</sup>In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages.

Molecular pharmaceutics·2026
Same journal

Mechanistic Insight into Self-Gelation Involved in Prescription Design for Optimization of Tablet Performance.

Molecular pharmaceutics·2026
Same journal

[<sup>68</sup>Ga]Ga-DOTA-DP-UBI 29-41: A Novel <sup>68</sup>Ga-Labeled Ubiquicidin 29-41 Derivative Containing d-Proline for Bacterial Infection PET Imaging.

Molecular pharmaceutics·2026
Same journal

Comparative Investigation of the Impact of Sodium Citrate Buffers on Lipid Nanoparticles of circRNA or Linear mRNA.

Molecular pharmaceutics·2026
Same journal

Preclinical Evaluation of <sup>177</sup>Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer.

Molecular pharmaceutics·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K

Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate.

Yan Ou1, Gina Chia-Yi Chu1, Ji Lyu1

  • 1Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States.

Molecular Pharmaceutics
|January 17, 2024
PubMed
Summary
This summary is machine-generated.

A novel drug conjugate targets prostate cancer (PC) cells and their mitochondria, effectively killing resistant cancer cells. This approach offers a promising new treatment strategy for metastatic castration-resistant prostate cancer (mCRPC).

Keywords:
conjugateheptamethine carbocyanine dyeprostate cancersimvastatintargeted therapy

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.0K

Related Experiment Videos

Last Updated: Jul 5, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.0K

Area of Science:

  • Oncology
  • Nanomedicine
  • Molecular Biology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) is a significant cause of cancer mortality in men.
  • Current treatments for mCRPC have limited efficacy and substantial side effects due to tumor resistance.
  • Targeted drug delivery systems are needed to improve treatment outcomes for advanced prostate cancer.

Purpose of the Study:

  • To evaluate a novel drug conjugate, simvastatin (SIM) linked to a tumor-targeting dye (DZ), for treating prostate cancer.
  • To assess the efficacy and mechanism of action of the DZ-SIM conjugate in preclinical models of prostate cancer.
  • To determine if the conjugate can overcome therapeutic resistance in prostate cancer cells.

Main Methods:

  • Synthesis and characterization of the DZ-SIM conjugate.
  • In vitro studies using prostate cancer cell lines to assess targeting specificity and cytotoxicity.
  • In vivo studies using xenograft tumor models to evaluate tumor suppression and host safety.

Main Results:

  • The DZ-SIM conjugate demonstrated specific targeting and effective killing of prostate cancer cells, irrespective of androgen receptor status or resistance.
  • DZ-SIM suppressed xenograft tumor growth in vivo without observable toxicity to normal host cells.
  • The conjugate localized to mitochondria within cancer cells, disrupting mitochondrial function and inducing cell death.

Conclusions:

  • The DZ-SIM conjugate represents a novel therapeutic strategy for prostate cancer, particularly mCRPC.
  • This targeted approach effectively overcomes therapeutic resistance by inducing mitochondrial dysfunction in cancer cells.
  • The conjugate shows potential as a more potent and specific treatment compared to traditional chemotherapeutics.